CRISPR THERAPEUTICS AG Debt Conversion, Converted Instrument, Amount
CRISPR THERAPEUTICS AG (CRSP) reported Debt Conversion, Converted Instrument, Amount of $61.93 million for the 12-month period ending 2016-12-31, per its 10-K filed 2019-02-25.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2019-02-25
- CRISPR THERAPEUTICS AG debt conversion, converted instrument, amount for the quarter ending 2016-12-31 was $0.00.
- CRISPR THERAPEUTICS AG debt conversion, converted instrument, amount for the quarter ending 2016-09-30 was $0.00.
- CRISPR THERAPEUTICS AG debt conversion, converted instrument, amount for the quarter ending 2016-06-30 was $0.00.
- CRISPR THERAPEUTICS AG debt conversion, converted instrument, amount for the quarter ending 2016-03-31 was $61.93M.
- CRISPR THERAPEUTICS AG debt conversion, converted instrument, amount for fiscal 2016 was $61.93M.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $0.00 derived: sum of 2 quarters · filed 2019-02-25 | $0.00 derived: sum of 3 quarters · filed 2019-02-25 | $61.93M 10-K · filed 2019-02-25 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $0.00 derived: sum of 2 quarters · filed 2017-11-08 | $61.93M 10-Q · filed 2017-11-08 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $61.93M 10-Q · filed 2017-08-10 | ||
| 2016-03-31 | $61.93M 10-Q · filed 2017-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |